Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/continuous-manufacturing-control-strategy-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Bioprocess Scale-UpContinuous Manufacturing Control Strategy Patents: Who Leads and Where the Field Is Still Open
- 43.0% concentration. The top 5 assignees hold 335 of 779 records in scope — filing here is already concentrated at the top rather than spread evenly.
- +155% filing growth. Filings rose from 20 in 2021 to 51 in 2024, the last year the data can be treated as complete.
- Control systems trail material science. G05B control & regulating claims sit at 15.8% of records, well behind G01N material analysis at 24.9% — the control layer is less claimed than the sensing layer.
779
Published Records
43%
Top-5 Share of All Records
+155%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (20 records) with 2024 (51) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 779 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this dataset covers
This landscape covers 779 published patent records filed between 2015 and mid-2026 that combine continuous manufacturing or real-time release claims with supporting control infrastructure — material traceability, diversion logic, process analytical technology, deviation handling or batch definition. It sits at the intersection of bioprocess engineering and industrial control systems, which is visible in the technology mix: material analysis, bioreactor hardware, and peptide/protein chemistry all outrank pure control-systems claims by record count.
Because publication typically lags filing by around 18 months, the most recent one or two years in any trend understate actual filing activity. The peak year so far is 2023, and the +155% growth figure from 2021 to 2024 uses the last year that can reasonably be treated as complete.
Filing activity and technology composition, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers
Filing trend and technology composition
Two views of the same 779 records: how filing volume has moved year over year, and how the underlying claims split across IPC subclasses. Because a single record can carry several IPC codes, the class shares below add up to more than 100% of the record total — that is expected, not an error.
Filing trend, 2017–2026
Filings climbed from 35 in 2017 to a peak of 132 in 2023, with the 2021→2024 span alone showing +155% growth (20 to 51 records). 2025 and 2026 figures are still filling in as publications catch up with filing dates, so they should not be read as a slowdown.
Technology composition by IPC subclass
G01N (material analysis & testing) leads at 24.9% of the 779 records, followed closely by C12M (bioreactors & enzyme apparatus) at 21.6% and C07K (peptides & proteins) at 20.5%. G05B (control & regulating systems) and A61K (medicinal preparations) sit in the mid-teens, while G06F (digital data processing), B01D (separation processes) and C12N (microorganisms & genetic engineering) each account for under 10% of records.
Shares are the percentage of the 779 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Continuous Manufacturing Control Strategy with Eureka
This page is one run against one query. Ask Eureka your own question about continuous manufacturing control strategy and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
A representative recent filing
Representative Filing
Modular process analytical technology testing apparatus (US20250290910A1)
ARRANTA BIO HOLDINGS, LLC
The invention provides a modular apparatus comprising at least one process analytical instrument and a controller adapted for fluid communication with a unit operation of a pharmaceutical or biopharmaceutical manufacturing system, systems comprising the modular apparatus, and related compositions and methods. The modular apparatuses described here and associated digital architecture provide a universal solution to fully integrate any pharmaceutical or biopharmaceutical manufacturing process using a wide range of process analytic tools.Filed by Arranta Bio Holdings, LLC and published September 2025, this filing sits squarely at the PAT/control-system boundary this dataset tracks.
Most-cited records in this landscape
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5566092A | Machine fault diagnostics system and method | 824 |
| 2 | US20120029720A1 | Dynamic distributed power grid control system | 326 |
| 3 | US6268853B1 | Data structure for use in enterprise controls | 320 |
| 4 | US6556950B1 | Diagnostic method and apparatus for use with enterprise control | 301 |
| 5 | US6157864A | System, method and article of manufacture for displaying an animated, realtime updated control sequence chart | 278 |
| 6 | US6108662A | System method and article of manufacture for integrated enterprise-wide control | 277 |
| 7 | US20040204775A1 | Economic calculations in process control system | 255 |
| 8 | US6161051A | System, method and article of manufacture for utilizing external models for enterprise wide control | 233 |
| 9 | US6618856B2 | Simulation method and apparatus for use in enterprise controls | 227 |
| 10 | US20040073404A1 | Mechanical-electrical template based method and apparatus | 216 |
Citation counts favour older records simply because they have had more time to accumulate citations inside the searched corpus — treat them as a signal of influence, not of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for filing strategy
Three read-throughs from the concentration, growth and citation data — useful for deciding where a new filing is likely to face dense prior art versus open space.
Concentration
43.0% / 5 assignees
of 779 records
Filing is already concentrated at the top
The top 5 assignees account for 43.0% of all 779 records in scope, and the top 10 combined reach 53.5%. That leaves a long tail of single- or few-filing entrants competing for the remaining claim space, which is where most freedom-to-operate analysis should focus.
Top 5: 335 of 779 records
Growth
+155%
2021 to 2024 filings
Filing activity has accelerated sharply
Filings grew from 20 in 2021 to 51 in 2024 — a +155% increase over that three-year span, with a peak of 132 records in 2023. This is a field still actively adding claims, not one that has settled.
Peak year: 2023 at 132 records
Technology split
24.9% vs 15.8%
G01N vs G05B share
Sensing claims outnumber control-logic claims
Material analysis and testing (G01N) covers 24.9% of the 779 records, while control & regulating systems (G05B) covers 15.8%. The gap suggests more contested ground in sensing and analytics than in the control-logic layer itself.
G01N 194 records; G05B 123 records
Filing geography
214 US filings
largest single office
US and EPO dominate the receiving offices
The United States accounts for 214 records, ahead of EPO at 105 and WIPO/PCT at 101. India, Australia and Israel each show meaningfully lower but still active filing counts, indicating this technology is being protected across multiple jurisdictions rather than filed once and left domestic.
US 214 · EPO 105 · WIPO 101
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous manufacturing control strategy, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the gaps sit
The ranking below covers the 100 companies the data endpoint returns for this search, ordered by record count — it is not a top-50 or top-100 cut, it is the entire ranked set. The leader holds 98 records; by fifth place that falls to 22, and by tenth place to 15, which is the shape of a field with one dominant filer and a long, thinner tail behind it.
Leader
98 records
leading assignee
One filer sits well ahead of the field
The leading assignee holds 98 records, more than four times the fifth-place holder's 22. That gap is unusually wide and points to a company that has built a deliberate filing programme around continuous manufacturing control rather than filing opportunistically.
Leader: 98 records
Mid-field drop-off
22 → 15
5th to 10th place
The drop from 5th to 10th place is gradual, not cliff-like
Fifth place holds 22 records and tenth place holds 15 — a gentler decline than the gap between first and fifth. This is where most active competitors sit, filing steadily rather than dominating.
5th: 22 · 10th: 15 records
Momentum
0 in latest year
several leaders
Several top filers show no output in the latest year
A number of the highest-ranked assignees, including some with year-over-year figures of -100%, show zero records in the latest tracked year. Given the roughly 18-month publication lag, this likely reflects filings still working through the pipeline rather than an actual stop in activity.
YoY momentum flagged for top assignees
Collaboration
10 pairs
co-assignee pairs
Co-filing is limited but not absent
Ten co-assignee pairs appear in the dataset, with the strongest pairing linked at 8 shared records. Most filers otherwise file independently, suggesting collaboration is the exception rather than the norm in this space.
Strongest pair: 8 shared records
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals Inc | 0 | -100% |
| Vertex Pharmaceuticals Inc | 0 | — |
| Genzyme Corp | 0 | -100% |
| Fisher Rosemount Systems Inc | 0 | — |
| Continuus Pharmaceuticals Inc | 0 | -100% |
| Johnson Controls Technology Company | 0 | — |
| Janssen Biotech Inc | 0 | — |
| Amgen Inc | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to a field with a dominant filer, a thinner competitive tail, and technology sub-areas that are claimed unevenly. The next steps depend on whether the goal is freedom-to-operate, whitespace filing, or watching a specific competitor.
Map claims against the leader's portfolio
With one assignee holding 98 records against a fifth-place count of 22, any new filing in this space should be checked against that leader's specific claim language before drafting begins.
Explore assignee portfolios in EurekaTest draft claims against under-claimed branches
Diversion logic, deviation-handling and batch-definition sub-areas show thinner filing density than the core sensing and bioreactor classes, which is where new claim language has more room to stand.
Run a whitespace check in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
One assignee leads the ranked field with 98 records, well ahead of the fifth-place holder at 22 and the tenth-place holder at 15. The top 5 assignees combined account for 43.0% of all 779 records in scope, and the top 10 combined reach 53.5%. That gap between the leader and the rest indicates a company running a sustained filing programme rather than occasional defensive filings, so competitive tracking should watch that leader's claim language closely.
Filing volume rose from 20 records in 2021 to 51 in 2024, a +155% increase over that three-year span, with the highest single year so far being 2023 at 132 records. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures are still incomplete and should not be read as the trend slowing down. The reliable growth read stops at 2024.
Material analysis and testing (IPC class G01N) covers the largest share at 24.9% of the 779 records, followed by bioreactor and enzyme apparatus (C12M) at 21.6% and peptide/protein chemistry (C07K) at 20.5%. Control and regulating systems (G05B) sit lower at 15.8%, meaning the sensing and material-analysis layer is more heavily claimed than the control-logic layer itself. Because records often carry multiple IPC codes, these percentages overlap rather than summing to 100%.
Sub-areas such as diversion logic automation, batch-definition boundary rules, deviation-handling decision trees and cross-site material traceability show thinner filing density than the dominant sensing and bioreactor classes. This does not mean these areas are unclaimed, but that the claim space is less occupied relative to G01N and C12M. A new filing with specific, narrowly drafted claims in these branches has more room to avoid dense prior art than one targeting core material-analysis claims.
US20250290910A1, filed by Arranta Bio Holdings and published in September 2025, describes a modular apparatus pairing a process analytical instrument with a controller for fluid communication with a unit operation in pharmaceutical or biopharmaceutical manufacturing. It is positioned as a universal integration layer across a wide range of process analytical tools rather than a single-sensor design. Because it sits at the PAT/control-system boundary this whole dataset tracks, it is a useful reference point for understanding how recent filings frame modular control architecture.
Answers are grounded in the same dataset. Derived from a Patsnap search on Continuous Manufacturing Control Strategy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Continuous Manufacturing Control Strategy in depth with Eureka
Go past this page: query the whole continuous manufacturing control strategy corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.